Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

14 mars 2019 uppdaterad av: Astellas Pharma Inc

A Phase 2, Clinical Pharmacological Study of ASP1941 in Japanese Patients With Type 1 Diabetes Mellitus

The objective of this study is to assess pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus when administered once daily (q.d.) for 2 weeks.

Studieöversikt

Status

Avslutad

Studietyp

Interventionell

Inskrivning (Faktisk)

43

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Aichi, Japan
        • Site JP00006
      • Fukuoka, Japan
        • Site JP00002
      • Gunma, Japan
        • Site JP00009
      • Ibaraki, Japan
        • Site JP00001
      • Kanagawa, Japan
        • Site JP00008
      • Kanagawa, Japan
        • Site JP00005
      • Okayama, Japan
        • Site JP00003
      • Osaka, Japan
        • Site JP00004
      • Osaka, Japan
        • Site JP00010
      • Osaka, Japan
        • Site JP00011
      • Tokyo, Japan
        • Site JP00007

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

20 år till 74 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

At the time of obtaining informed consent:

  • Subject is diagnosed with type 1 diabetes mellitus and has been treated with insulin therapy for at least 52 weeks (364 days).
  • Subject is able to be admitted to the site as scheduled.
  • Subject is able to record in Patient's diary from the first study drug dose in observation period until the day before the end of post observation.

At screening period:

  • Subject has an HbA1c (NGSP) value of between 7.5% and 10.0%. If subject has an HbA1c value of between 7.3% and 10.2% (out of the reference range), HbA1c may be re-measured only once within the allowance range in screening period. Re-measured HbA1c (NGSP) value will be adopted for the determination.
  • Subject has been receiving insulin therapy at daily doses (instructed by a doctor) within a ±20% range for at least 12weeks (83days) prior to the start of screening.
  • Subject has a fasting serum C-peptide level ≤0.5 ng/mL at screening.
  • Subject receives treatments for complications (except for transient diseases such as a cold) that, in the investigator's or sub-investigator's opinion, need not to be changed during the period from the start of screening to the end of the treatment period.
  • Subject has body mass index (BMI) value of 20.0 to 35.0 kg/m2 at screening.

Exclusion Criteria:

At the time of obtaining informed consent:

  • Subject has type 2 diabetes mellitus.
  • Subject has participated or has been participating in a clinical study or a post marketing study of another drug or medical equipment within 12 weeks (84 days) prior to obtaining informed consent.
  • Subject has received ASP1941 (ipragliflozin) with the exception of placebo.

At screening period:

  • Subject has proliferative retinopathy (subjects with stable condition after photocoagulation etc. may be enrolled in the study).
  • Subject has developed hypoglycemia unawareness (requires help of a third person) or severe hypoglycemia (diabetic coma, precoma, or convulsion) within 12 weeks (84 days) prior to the start of screening.
  • Subject has developed diabetic ketoacidosis within 12 weeks (84 days) prior to the start of screening.
  • Subject has chronic disease(s) which require the continuous use of corticosteroids or immunosuppressants (oral administration, injection, inhalation, or suppository).
  • Subject has received hypoglycemic agent(s) other than insulin within 12 weeks (83 days) prior to the start of screening.
  • Subject with perioperative, severe infection or serious injury.
  • Subject whose serum creatinine value exceeds the upper limit of normal range at screening.
  • Subject has a urinary albumin/urinary creatinine ratio>300 mg/g in urinalysis at screening.
  • Subject has a history of clinically significant renal disease(s) such as renovascular occlusive disease, nephrectomy, and/or renal transplant.
  • Subject has AST and ALT >2 ×ULN or T-Bil >1.5 × ULN at screening, or has a history of serious hepatic diseases.
  • Subject presents with symptoms of dysuria, anuria, oliguria and urinary retention.
  • Subject has a history of recurrent urinary tract infections and recurrent genital infections (developed 3 times or more within 24 weeks (168 days) prior to the start of screening).
  • Subject has urinary tract infection or genital infection with subjective symptoms.
  • Subject has a history of angina unstable, myocardial infarction, angioplasty, and serious heart disease (NYHA Class II-IV) within 24 weeks (168 days) prior to the start of screening, or has complications of heart disease that, in the investigator's or sub-investigator's opinion, may interfere with the evaluation of safety of ASP1941.
  • Subject has uncontrolled blood pressure (systolic blood pressure≥160 mmHg or diastolic blood pressure≥100 mmHg in the supine position after a 5-minute rest at screening ).
  • Subject has serious gastrointestinal disease or a history of serious gastrointestinal operation.
  • Subject has malignant tumors concomitantly (subject may be enrolled in the study if the subject has a history of a malignant tumor which has not recurred without any treatment within 5 years prior to the start of screening).
  • Subject has psychiatric disorder that makes the subject unsuitable for study participation.
  • Subject has drug addiction or alcohol abuse.
  • Subject has a history of drug allergies.
  • Subject is unable to adhere to any of the compliance such as hospital visits and dose instruction specified in this study, or does not agree with it.
  • Subject has donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days prior to the start of screening.
  • Subject has any condition that, in the investigator's or sub-investigator's opinion, makes the subject unsuitable for study participation.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo
en gång om dagen
Oral
Experimentell: ASP1941 Low dose group
once daily
Oral
Andra namn:
  • Suglat
  • Ipragliflozin
Experimentell: ASP1941 Middle dose group
once daily
Oral
Andra namn:
  • Suglat
  • Ipragliflozin
Experimentell: ASP1941 High dose group
once daily
Oral
Andra namn:
  • Suglat
  • Ipragliflozin

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Daily profile of plasma glucose levels
Tidsram: up to Day 14
up to Day 14
Area under the concentration-time curve (AUC) 0-24hr (AUC0-24h) of plasma glucose levels
Tidsram: at Day -1, Day 1 and Day 14
at Day -1, Day 1 and Day 14
AUC0-3h of plasma glucose levels
Tidsram: at Day -1, Day 1 and Day 14
at Day -1, Day 1 and Day 14
AUC0-4h of plasma glucose levels
Tidsram: up to Day 14
up to Day 14
AUC0-10h of plasma glucose levels
Tidsram: up to Day 14
up to Day 14
Fasting plasma glucose levels
Tidsram: up to Day 21
up to Day 21
Glycoalbumin
Tidsram: up to Day 21
up to Day 21
Urinary glucose excretion
Tidsram: up to Day 14
up to Day 14
Urinary glucose excretion rate
Tidsram: up to Day 14
up to Day 14
Urine volume
Tidsram: up to Day 14
up to Day 14
Urinary glucose concentration
Tidsram: up to Day 15
up to Day 15
Body weight
Tidsram: up to Day 21
up to Day 21
Renal glucose clearance
Tidsram: up to Day 14
up to Day 14
Plasma concentration of unchanged ASP1941
Tidsram: up to Day 14
up to Day 14
Urinary concentration of unchanged ASP1941
Tidsram: up to Day 14
up to Day 14
Pharmacokinetics (PK) parameter of ASP1941 in plasma: AUC from time 0 extrapolated to infinity (AUCinf)
Tidsram: at Day 1
at Day 1
PK parameter of ASP1941 in plasma: AUC from the time of dosing to the last measurable concentration (AUClast)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: AUC from the time of dosing to 24 hr (AUC0-24h)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Oral Clearance (CL/F)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Maximum concentration (Cmax)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Terminal Elimination Half-life (t1/2)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma: Time of the Maximum Concentration (tmax)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in urine: Amount excreted in urine between time (Ae)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in urine: % of the dose of excreted in urine (Ae%)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
PK parameter of ASP1941 in plasma and urine: Renal Clearance (CLr)
Tidsram: at Day 1 and Day 14
at Day 1 and Day 14
Safety assessed by vital signs
Tidsram: up to Day 21
Supine blood pressure and supine pulse rate
up to Day 21
Safety assessed by 12-lead electrocardiogram
Tidsram: up to Day 21
up to Day 21
Safety assessed by laboratory tests
Tidsram: up to Day 21
Hematology, biochemistry and urinalysis
up to Day 21
Safety assessed by self-monitored blood glucose levels
Tidsram: up to Day 21
up to Day 21
Safety assessed by Adverse events
Tidsram: up to Day 21
up to Day 21

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 september 2015

Primärt slutförande (Faktisk)

19 mars 2016

Avslutad studie (Faktisk)

19 mars 2016

Studieregistreringsdatum

Först inskickad

18 augusti 2015

Först inskickad som uppfyllde QC-kriterierna

19 augusti 2015

Första postat (Uppskatta)

20 augusti 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 mars 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 mars 2019

Senast verifierad

1 mars 2019

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

Nej

IPD-planbeskrivning

Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera